Novocure™ Announces Data Presentations of NovoTTF-100A System™ at the 16th Annual Scientific Meeting of the Society for NeuroOncology

Nov 17, 2011, 13:46 ET from Novocure

PORTSMOUTH, N. H., Nov. 17, 2011 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced the presentation of several studies evaluating the NovoTTF-100A System™ for the treatment of recurrent glioblastoma at the 16th Annual Scientific Meeting of the Society of NeuroOncology, November 17-20 in Anaheim, California.

Data from the following studies will be presented at this meeting:

Mitosis Interference of Cancer Cells during Anaphase by Electric Field from NovoTTF-100A

Presenter:  Dr. Eric T. Wong, Beth Israel Deaconess Medical Center, Boston, MA
Date/Time:  Friday, November 18, 7:30 pm9:00 pm
Session:  Poster Viewing Reception I
Abstract #CB-17

Comparing the Effect of NovoTTF-100A to Bevacizumab in Recurrent GBM: A Post-Hoc Sub-Analysis of the Phase III Trial Data

Presenter:  Dr. Zvi Ram, Tel Aviv Medical Center, Tel Aviv, Israel
Date/Time:  Saturday, November 19, 5:00 pm7:00 pm
Session:  Poster Viewing Reception II
Abstract #NO-50

Updated Survival Data of the Phase III Clinical Trial of NovoTTF-100A versus Best Standard Chemotherapy for Recurrent Glioblastoma

Presenter:  Dr. Eric T. Wong, Beth Israel Deaconess Medical Center, Boston, MA
Date/Time:  Sunday, November 20, 11:15 am11:30 am
Session:  Plenary – Medical and Neuro-Oncology -2

About Glioblastoma

Glioblastoma multiforme (GBM) is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year.  The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment.  The disease is widely recognized as one of the most aggressive and deadly forms of cancer.  

About the NovoTTF-100A System™

NovoTTF-100A System™ is a portable, non-invasive medical device designed for continuous use throughout the day by the patient.  The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate.  The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.  In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life without many of the side effects of chemotherapy.  The NovoTTF-100A has received marketing approval in the US and is a CE Marked device that is cleared for sale in Europe.

The US Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically – or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy.  The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device.

About Novocure™

Novocure™ Limited is a private oncology company pioneering a novel therapy for solid tumors.  Novocure's worldwide headquarters is located in the Jersey Isle.  Novocure's US operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel.  For additional information about the company, please visit

SOURCE Novocure